Since the half-lives of AFP and DCP are approximately 4 and 2.5 days, respectively, post-treatment levels of tumor markers obtained at the first postoperative follow-up visit of patients in our study (within 1-2 months post-hepatectomy) were largely unaffected by baseline levels of tumor markers before treatment (23). The gene discussed is ACE; the disease is neoplasm.